Institutional review board permission is not required for conducting systematic review and meta-analysis
Active Ingredient: semaglutide
Contact your provider promptly if you have: Persistent vomiting or inability to keep fluids down Severe or worsening abdominal pain Signs of dehydration (dizziness, very dark urine, fainting, rapid heartbeat) Severe constipation lasting multiple days with significant pain Symptoms that interfere with daily function or do not improve after supportive changes Discuss dose and timing adjustments If side effects are strong after a dose increase, your clinician may consider slowing the titration, changing supportive strategies, or reviewing nutrition and hydration
Watching how BioCare and Robard think about this, especially in the context of telehealth, made the next step feel obvious
PLOS ONE, 6 (7), e22564.
To ground these concepts, I present a case-oriented rationale : a scenario in which a patient on high-dose basal insulin exhibits evidence of over-basalization, persistent hyperglycemia, and cardiometabolic comorbidities